Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Author(s):
Pollack, C.V.; Reilly, P.A.; Bernstein, R.; Dubiel, R.; Eikelboom, J.; Glund, S.; Huisman, M.V. (0000-0003-1423-5348); Hylek, E.; Kam, C.W.; Kamphuisen, P.W.; Kreuzer, J.; Levy, J.H.; Sellke, F.; Stangier, J.; Steiner, T.; Wang, B.S.; Weitz, J.I.
Published
2015
Publication type
Article / Letter to editor
Date issued
2015-07-31
Language
English
Is part of
Thrombosis and Haemostasis (2015), Vol. 114, no. 1, p. 198-205
hdl
1887/107524
doi
10.1160/TH15-03-0192